Mani Foroohar
Stock Analyst at Leerink Swann
(2.23)
# 2,689
Out of 4,944 analysts
166
Total ratings
48.89%
Success rate
-7.21%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Mani Foroohar
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SRPT Sarepta Therapeutics | Downgrades: Market Perform | $45 → $10 | $18.80 | -46.81% | 2 | Jul 21, 2025 | |
| RCKT Rocket Pharmaceuticals | Downgrades: Market Perform | $37 → $8 | $2.91 | +174.91% | 12 | May 28, 2025 | |
| LXEO Lexeo Therapeutics | Maintains: Outperform | $19 → $18 | $4.67 | +285.44% | 3 | Mar 24, 2025 | |
| RXRX Recursion Pharmaceuticals | Maintains: Market Perform | $7 → $6 | $5.41 | +10.91% | 8 | Feb 28, 2025 | |
| FDMT 4D Molecular Therapeutics | Maintains: Outperform | $31 → $27 | $6.15 | +339.02% | 9 | Jan 13, 2025 | |
| NGNE Neurogene | Maintains: Outperform | $45 → $72 | $19.17 | +275.59% | 2 | Nov 12, 2024 | |
| CAMP Camp4 Therapeutics | Initiates: Outperform | $17 | $1.38 | +1,131.88% | 1 | Nov 5, 2024 | |
| MIRM Mirum Pharmaceuticals | Maintains: Outperform | $47 → $49 | $64.72 | -24.29% | 11 | Oct 17, 2024 | |
| BBIO BridgeBio Pharma | Maintains: Outperform | $47 → $46 | $49.09 | -6.29% | 15 | Oct 17, 2024 | |
| WVE Wave Life Sciences | Maintains: Outperform | $20 → $22 | $8.45 | +160.36% | 6 | Oct 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $53 → $62 | $41.41 | +49.72% | 15 | Jul 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $13 | $12.39 | +4.92% | 1 | Jul 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $29 | $18.85 | +53.85% | 1 | Jul 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $12 → $4 | $5.47 | -26.87% | 2 | Apr 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $8.10 | - | 10 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $31 | $3.64 | +751.65% | 1 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $7 | $0.76 | +824.70% | 1 | Nov 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $40 | $17.80 | +124.72% | 12 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $111 → $93 | $25.66 | +262.43% | 17 | Feb 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $86 → $84 | $10.86 | +673.48% | 4 | Jan 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $6 → $7 | $2.29 | +205.68% | 4 | Jan 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $81 → $77 | $16.86 | +356.70% | 2 | Jan 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $144 → $143 | $429.93 | -66.74% | 11 | Jan 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $5 → $6 | $6.38 | -5.96% | 5 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $75 → $76 | $56.60 | +34.28% | 1 | Nov 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $34 | $1.79 | +1,799.44% | 4 | May 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $50 → $20 | $2.47 | +709.72% | 6 | Jul 23, 2021 |
Sarepta Therapeutics
Jul 21, 2025
Downgrades: Market Perform
Price Target: $45 → $10
Current: $18.80
Upside: -46.81%
Rocket Pharmaceuticals
May 28, 2025
Downgrades: Market Perform
Price Target: $37 → $8
Current: $2.91
Upside: +174.91%
Lexeo Therapeutics
Mar 24, 2025
Maintains: Outperform
Price Target: $19 → $18
Current: $4.67
Upside: +285.44%
Recursion Pharmaceuticals
Feb 28, 2025
Maintains: Market Perform
Price Target: $7 → $6
Current: $5.41
Upside: +10.91%
4D Molecular Therapeutics
Jan 13, 2025
Maintains: Outperform
Price Target: $31 → $27
Current: $6.15
Upside: +339.02%
Neurogene
Nov 12, 2024
Maintains: Outperform
Price Target: $45 → $72
Current: $19.17
Upside: +275.59%
Camp4 Therapeutics
Nov 5, 2024
Initiates: Outperform
Price Target: $17
Current: $1.38
Upside: +1,131.88%
Mirum Pharmaceuticals
Oct 17, 2024
Maintains: Outperform
Price Target: $47 → $49
Current: $64.72
Upside: -24.29%
BridgeBio Pharma
Oct 17, 2024
Maintains: Outperform
Price Target: $47 → $46
Current: $49.09
Upside: -6.29%
Wave Life Sciences
Oct 16, 2024
Maintains: Outperform
Price Target: $20 → $22
Current: $8.45
Upside: +160.36%
Jul 24, 2024
Upgrades: Outperform
Price Target: $53 → $62
Current: $41.41
Upside: +49.72%
Jul 22, 2024
Initiates: Outperform
Price Target: $13
Current: $12.39
Upside: +4.92%
Jul 2, 2024
Initiates: Outperform
Price Target: $29
Current: $18.85
Upside: +53.85%
Apr 25, 2024
Downgrades: Market Perform
Price Target: $12 → $4
Current: $5.47
Upside: -26.87%
Mar 6, 2024
Upgrades: Outperform
Price Target: n/a
Current: $8.10
Upside: -
Feb 20, 2024
Initiates: Outperform
Price Target: $31
Current: $3.64
Upside: +751.65%
Nov 30, 2023
Initiates: Outperform
Price Target: $7
Current: $0.76
Upside: +824.70%
May 12, 2023
Downgrades: Market Perform
Price Target: $40
Current: $17.80
Upside: +124.72%
Feb 24, 2023
Downgrades: Underperform
Price Target: $111 → $93
Current: $25.66
Upside: +262.43%
Jan 23, 2023
Maintains: Outperform
Price Target: $86 → $84
Current: $10.86
Upside: +673.48%
Jan 23, 2023
Maintains: Market Perform
Price Target: $6 → $7
Current: $2.29
Upside: +205.68%
Jan 23, 2023
Maintains: Outperform
Price Target: $81 → $77
Current: $16.86
Upside: +356.70%
Jan 23, 2023
Maintains: Market Perform
Price Target: $144 → $143
Current: $429.93
Upside: -66.74%
Nov 14, 2022
Maintains: Market Perform
Price Target: $5 → $6
Current: $6.38
Upside: -5.96%
Nov 7, 2022
Maintains: Outperform
Price Target: $75 → $76
Current: $56.60
Upside: +34.28%
May 12, 2022
Maintains: Outperform
Price Target: $30 → $34
Current: $1.79
Upside: +1,799.44%
Jul 23, 2021
Maintains: Market Perform
Price Target: $50 → $20
Current: $2.47
Upside: +709.72%